trial

The Purpose of This Study is to Determine the Safety, Tolerability, and Pharmacokinetics of Brexpiprazole Long-acting Injection Following a Single Administration in Healthy Subjects/Patients With Schizophrenia.

NCTId NCT06674694
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Recruiting
Enrollment 56 (estimated)
Sponsored by Sichuan Kelun Pharmaceutical Co.,Ltd.
Primary completion 2026-06-30
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Recruiting
Enrollment
56 (estimated)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2024-04-10
Primary completion
2026-06-30
Eligibility
ALL · 18 Years · 65 Years

Interventions & indications

Drugs
Brexpiprazole (Rexulti)

Sponsors

Sichuan Kelun Pharmaceutical Co.,Ltd.Lead Sponsor

Sites

1 total
Beijing, China

Facts & assertions

4 sourced
Enrollment
56
Phase
PHASE1
Primary Completion Date
2026-06-30
Status
RECRUITING
relationships
The graph out of here
drug
Brexpiprazole (Rexulti)
drug
lead_sponsor
Sichuan Kelun Pharmaceutical Co.,Ltd.
company
indication
Schizophrenia Disorders
indication
Schizophrenia
indication